ARTICLE | Clinical News
Tecarfarin: SPA received
May 5, 2014 7:00 AM UTC
Armetheon received an SPA from FDA for an open-label Phase III trial to evaluate oral tecarfarin as an anticoagulant in 3,000 patients. The company expects to start the trial in 1Q15. ...